Events calendar

Back to events
29
may

Clinical Pharmacology Studies with Cannabis or Specific Cannabinoids

Tuesday May 29, 2018

18:30 - 21:00

Pub L’île Noire, 1649 rue St-Denis Montréal (Québec) H2X 3K4 View Google Maps

BioTech Annecto Montreal is pleased to announce a presentation given by

Michael Kong, PhD, Director, Medical Science Liaison (speaking on behalf of Graham Wood, PhD, Chief R&D Officer) at Altasciences Clinical Research (Algorithme Pharma ), entitled:

Clinical Pharmacology Studies with Cannabis or Specific Cannabinoids

Cannabis has been used for years as a medicinal product. However, only a few cannabis-based therapies have proceeded through regulatory approval as drugs or botanicals. With the huge interest in the ability of cannabis or products with specific cannabinoids to treat a wide range of therapeutic areas, there are now a number of sponsors looking at the drug or botanical approval pathway with Health Canada and the FDA. This presentation will review the regulatory pathways that can be used for cannabis-based therapies. We will also review the clinical pharmacology studies that will be required for approval, starting with first-in-human studies and including the later stage

BioTech Annecto Montreal is pleased to announce a presentation given by

Michael Kong, PhD, Director, Medical Science Liaison (speaking on behalf of Graham Wood, PhD, Chief R&D Officer) at Altasciences Clinical Research (Algorithme Pharma ), entitled:

Clinical Pharmacology Studies with Cannabis or Specific Cannabinoids

Cannabis has been used for years as a medicinal product. However, only a few cannabis-based therapies have proceeded through regulatory approval as drugs or botanicals. With the huge interest in the ability of cannabis or products with specific cannabinoids to treat a wide range of therapeutic areas, there are now a number of sponsors looking at the drug or botanical approval pathway with Health Canada and the FDA. This presentation will review the regulatory pathways that can be used for cannabis-based therapies. We will also review the clinical pharmacology studies that will be required for approval, starting with first-in-human studies and including the later stage studies, such as human abuse potential or testing drug effects on driving performance.

Dr. Wood has a Ph.D. in Neurology and Neurosurgery from McGill University. He joined Altasciences Clinical Research as Executive Vice President, Phase I Clinical Development, in November 2015. Since 1999, his focus has been on clinical pharmacology, managing three new molecular entities from toxicology to Phase IIa and over twenty from first-in-human to Phase IIa. Dr. Wood has conducted over 400 clinical pharmacology studies with companies such as Phoenix International, MDS Pharma, Allied Research and Cetero. Dr. Wood’s roles have varied from Project Management, Business Development and Clinical Operations. More recently, he was CEO at Manna Research (a late phase clinical CRO) and Chief Science Officer at Akesis.

Who is invited?
Professionals in the following industries: pharmaceuticals, CROs, biotechnology, and medical technology, Health care and biomedical research

People seeking opportunities to enlarge their professional network in life science industries.

When and Where?
6:30pm to 9pm on Tuesday May 29, 2018

Pub L’île Noire
1649 rue St-Denis
Montréal (Québec)
H2X 3K4

Cost: $15 (up to 48h before the event) / $20 regular price / FREE if you purchase a yearly membership

Share this event: LinkedIn Twitter Email

Similar events

Submit an event

You want to share your event with members of the life sciences industry and health technology?

Fill out this form and we will be happy to add it to our calendar.

Submit an event
X

Subscribe to industry news

Which mailing list do you want to subscribe?

Flash InVivo
Info InVivo
Mailing list

What is your preferred language ?

French
English